JFrog Ltd. (FROG) Stock Falls on Q4 2025 Earnings

Bio-Rad Laboratories Inc. (BIO) reported fourth-quarter 2025 results. Revenue rose 3.85% year-over-year to $693.2 million, slightly below the consensus estimate of $700.9 million.

Total revenue: $693.2 million (+3.85% year-over-year).

Gross profit: $345.2 million (+0.97% year-over-year).

Cost of sales: $348.0 million (+6.88% year-over-year).

Operating result: operating loss of $118.9 million (down 303.95% year-over-year).

Net income attributable to common shareholders: $720.0 million (down 200.59% year-over-year).

Diluted earnings per share: 26.65 (down 204.63% year-over-year) versus an estimate of 2.74.

Cash from operating activities: $164.9 million (+32.77% year-over-year).

Capital expenditures (purchases of property, plant and equipment): $31.7 million (down 26.11% year-over-year).

Cash and cash equivalents: $529.8 million (+8.54% year-over-year).

Total liabilities: $3.12 billion (+11.74% year-over-year).

Key takeaways:

Top-line growth was modest but missed the revenue estimate.

Gross profit was relatively flat while cost of sales increased at a faster pace.

Operating performance moved to a sizable loss, even as reported net income remained at $720.0 million.

Operating cash flow strengthened year-over-year, supporting liquidity.

Balance sheet shows a healthy cash position alongside rising liabilities.

Note: This financials data is sourced from a third-party provider and has not been independently verified by Quiver.

Bio-Rad Laboratories Inc. Hedge Fund Activity

We have seen 184 institutional investors add shares of Bio-Rad Laboratories Inc. stock to their portfolio, and 198 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC added 777,593 shares (+4642.6%) to their portfolio in Q3 2025, for an estimated $218,029,301
MASSACHUSETTS FINANCIAL SERVICES CO /MA/ added 390,593 shares (+4534.4%) to their portfolio in Q4 2025, for an estimated $118,345,773
SELECT EQUITY GROUP, L.P. removed 255,989 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $71,776,755
MILLENNIUM MANAGEMENT LLC removed 227,393 shares (-90.3%) from their portfolio in Q3 2025, for an estimated $63,758,723
MANGROVE PARTNERS IM, LLC added 126,853 shares (+inf%) to their portfolio in Q3 2025, for an estimated $35,568,312
SCOPIA CAPITAL MANAGEMENT LP removed 94,737 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $26,563,307
EXODUSPOINT CAPITAL MANAGEMENT, LP removed 85,134 shares (-78.4%) from their portfolio in Q3 2025, for an estimated $23,870,722

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

Bio-Rad Laboratories Inc. Government Contracts

We have seen $3,768,078 of award payments to $BIO over the last year.

Here are some of the awards which we have have seen pay out the most over the last year:

IMMUNOLOGY: $396,950
SEROLOGICAL AUTOMATED ANALYZERS FOR HUMAN IMMUNODEFICIENCY VIRUS AND HEPATITIS C VIRUS TESTING FOR MILITARY...: $349,963
CONSUMABLES AND REAGENT PRODUCTS FOR SEROLOGICAL AUTOMATED ANALYZER SYSTEMS.: $244,260
HIV DIAGNOSTICS LABORATORY CONSUMABLES AND REAGENTS FOR BIO-RAD EQUIPMENT: $211,619
BIOPLEX REAGENTS AND CONSUMABLES: $200,000

To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.

Bio-Rad Laboratories Inc. Analyst Ratings

Wall Street analysts have issued reports on $BIO in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Citigroup issued a "Buy" rating on 10/30/2025

To track analyst ratings and price targets for Bio-Rad Laboratories Inc., check out Quiver Quantitative's $BIO forecast page.

Bio-Rad Laboratories Inc. Price Targets

Multiple analysts have issued price targets for $BIO recently. We have seen 2 analysts offer price targets for $BIO in the last 6 months, with a median target of $357.5.

Here are some recent targets:

Brandon Couillard from Wells Fargo set a target price of $340.0 on 10/30/2025
Patrick Donnelly from Citigroup set a target price of $375.0 on 10/30/2025